Clinical Trial of the Dual Vector Base Editor for the Treatment of the CHD3-R1025W Mutation

计划入组 1 人 · 首次发布于 2025 年 3 月 6 日

4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF

计划入组 2,011 人 · 首次发布于 2014 年 4 月 15 日

EuroPainClinicsStudy X

计划入组 180 人 · 首次发布于 2021 年 4 月 22 日

HG-205

TUN-X,X

TTR base editor (Beam Therapeutics)

Molecule X LLC

Mexico

SFJ Pharmaceuticals X, LTD.

X-Pert-Med GmbH

Germany

Scribe Therapeutics' CRISPR Therapies Show Promise in Cardiometabolic Disease Treatment

Scribe Therapeutics to Present Novel CRISPR-Based Gene Therapy Data for Duchenne Muscular Dystrophy at ASGCT 2025

Scribe Therapeutics Demonstrates Breakthrough CRISPR Therapy for Cardiovascular Disease with >90% Lp(a) Reduction